Ranjit Philip1,2, B Rush Waller1,2, Vijaykumar Agrawal3, Dena Wright1,2, Alejandro Arevalo1,2, David Zurakowski4, Shyam Sathanandam1,2. 1. Division of Pediatric Cardiology, University of Tennessee Health Science Center, Le Bonheur Children's Hospital, Memphis, Tennessee. 2. Department of Pediatrics, University of Tennessee Health Science Center, Le Bonheur Children's Hospital, Memphis, Tennessee. 3. Department of Radiology, University of Tennessee Health Science Center, Le Bonheur Children's Hospital, Memphis, Tennessee. 4. Department of Biostatistics, Harvard Medical School, Boston, Massachusetts.
Abstract
OBJECTIVES: The aim of this study was to describe and differentiate the morphology of patent ductus arteriosus (PDA) seen in children born prematurely from other PDA types. BACKGROUND: PDAs are currently classified as types A-E using the Krichenko's classification. Children born prematurely with a PDA morphology that did not fit this classification were described as Type F PDA. METHODS: A review of 100 consecutive children who underwent transcatheter device closure of PDA was performed. The diameter and length (L) of the PDA and the device diameter (D) were indexed to the descending aorta (DA) diameter. RESULTS: Comparison of 26 Type F PDAs was performed against, 29 Type A, 7 Type C and 32 Type E PDAs. Children with Type F PDAs (median 27.5 weeks gestation) were younger during the device occlusion compared with types A, C, and E (median age: 6 vs. 32, 11, and 42 months; P = 0.002). Type F PDAs were longer and larger, requiring a relatively large device for occlusion than types A, C, and E (Mean L/DA: 1.88 vs. 0.9, 1.21, and 0.89, P ≤ 0.01 and Mean D/DA: 1.04 vs. 0.46, 0.87, and 0.34, P ≤0.01). The Amplatzer vascular plug-II (AVP-II) was preferred for occlusion of Type F PDAs (85%; P <0.001). CONCLUSIONS: Children born prematurely have relatively larger and longer PDAs. These "fetal type PDAs" are best classified separately. We propose to classify them as Type F PDAs to add to types A-E currently in use. The AVP-II was effective in occluding Type F PDAs.
OBJECTIVES: The aim of this study was to describe and differentiate the morphology of patent ductus arteriosus (PDA) seen in children born prematurely from other PDA types. BACKGROUND: PDAs are currently classified as types A-E using the Krichenko's classification. Children born prematurely with a PDA morphology that did not fit this classification were described as Type F PDA. METHODS: A review of 100 consecutive children who underwent transcatheter device closure of PDA was performed. The diameter and length (L) of the PDA and the device diameter (D) were indexed to the descending aorta (DA) diameter. RESULTS: Comparison of 26 Type F PDAs was performed against, 29 Type A, 7 Type C and 32 Type E PDAs. Children with Type F PDAs (median 27.5 weeks gestation) were younger during the device occlusion compared with types A, C, and E (median age: 6 vs. 32, 11, and 42 months; P = 0.002). Type F PDAs were longer and larger, requiring a relatively large device for occlusion than types A, C, and E (Mean L/DA: 1.88 vs. 0.9, 1.21, and 0.89, P ≤ 0.01 and Mean D/DA: 1.04 vs. 0.46, 0.87, and 0.34, P ≤0.01). The Amplatzer vascular plug-II (AVP-II) was preferred for occlusion of Type F PDAs (85%; P <0.001). CONCLUSIONS:Children born prematurely have relatively larger and longer PDAs. These "fetal type PDAs" are best classified separately. We propose to classify them as Type F PDAs to add to types A-E currently in use. The AVP-II was effective in occluding Type F PDAs.
Authors: A Rodríguez Ogando; I Planelles Asensio; A Rodríguez Sánchez de la Blanca; F Ballesteros Tejerizo; M Sánchez Luna; J M Gil Jaurena; C Medrano López; J L Zunzunegui Martínez Journal: Pediatr Cardiol Date: 2017-11-08 Impact factor: 1.655
Authors: Michael L O'Byrne; Marisa E Millenson; Connor B Grady; Jing Huang; Nicolas A Bamat; David A Munson; Lihai Song; Yoav Dori; Matthew J Gillespie; Jonathan J Rome; Andrew C Glatz Journal: Am Heart J Date: 2019-08-17 Impact factor: 4.749
Authors: Shyam Sathanandam; Dan Gutfinger; Brian Morray; Darren Berman; Matthew Gillespie; Thomas Forbes; Jason N Johnson; Ruchira Garg; Sophie Malekzadeh-Milani; Alain Fraisse; Osman Baspinar; Evan M Zahn Journal: Pediatr Cardiol Date: 2021-06-30 Impact factor: 1.655